BrightGene Bio Medical Technology C (688166) — Capital Reinvestment Ratio
BrightGene Bio Medical Technology C (688166) has a Capital Reinvestment Ratio of 2.55x as of June 2023, meaning it reinvests 3% of its operating cash flow (CN¥26.70 Million) in capital expenditures (CN¥68.06 Million). See cash generation quality of BrightGene Bio Medical Technology C to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BrightGene Bio Medical Technology C Capital Reinvestment Ratio (2016–2024)
This chart tracks BrightGene Bio Medical Technology C's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for BrightGene Bio Medical Technology C (2016–2024)
Year-by-year Capital Reinvestment Ratio for BrightGene Bio Medical Technology C from 2016 to 2024. For live market cap and broader valuation context, see market cap of BrightGene Bio Medical Technology C.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.05x | CN¥245.56 Million | CN¥257.20 Million | ▼ -47.6% |
| 2023 | 2.00x | CN¥194.77 Million | CN¥389.33 Million | ▼ -14.4% |
| 2022 | 2.33x | CN¥311.26 Million | CN¥726.73 Million | ▼ -54.8% |
| 2021 | 5.17x | CN¥176.08 Million | CN¥909.66 Million | ▲ +126.0% |
| 2020 | 2.29x | CN¥155.43 Million | CN¥355.27 Million | ▲ +56.6% |
| 2019 | 1.46x | CN¥61.33 Million | CN¥89.54 Million | ▼ -16.9% |
| 2018 | 1.76x | CN¥63.99 Million | CN¥112.47 Million | ▼ -24.9% |
| 2017 | 2.34x | CN¥35.77 Million | CN¥83.70 Million | ▲ +90.2% |
| 2016 | 1.23x | CN¥29.73 Million | CN¥36.58 Million | — |